NCT00118040 - Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2005

Primary Completion Date

August 15, 2010

Study Completion Date

August 15, 2010

Conditions

Recurrent Bladder CarcinomaStage I Bladder Cancer AJCC v6 and v7Stage II Bladder Cancer AJCC v6 and v7Stage III Bladder Cancer AJCC v6 and v7

Interventions

DRUG

Genistein

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Placebo Administration

Given orally

PROCEDURE

Therapeutic Conventional Surgery

Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.

Trial Locations (10)

11530

AccuMed Research Associates, Garden City

14642

University of Rochester, Rochester

35233

University of Alabama at Birmingham Cancer Center, Birmingham

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53188

ProHealth Waukesha Memorial Hospital, Waukesha

53792

University of Wisconsin Hospital and Clinics, Madison

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

78229

Urology San Antonio Research PA, San Antonio

92653

South Orange County Surgical Medical Group Inc, Laguna Hills

53706-1969

University of Wisconsin Chemoprevention Consortium, Madison

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH